• people
  • current
  • alumni
• mission
• themes
  • pluripotent stem cells
  • erythropoietin and cancer
  • pharmacologically regulated cell therapy
  • genome architecture
  • a smarter war on cancer
• papers
• collaborators
• news
• links
• upcoming
• fun
• contact

papers

Pluripotent Stem Cells - Our Papers

Ware CB, Chien S, and Blau CA. Slow, Controlled-Rate Freezing Improves Human Embryonic Stem Cell Survival. Biotechniques 38:879-883, 2005.

Ware CB, Nelson, AM, and Blau CA. A Comparison of NIH-Approved Human Embryonic Stem Cell Lines. Stem Cells 24:2677-84, 2006.

Wang L, Schulz TC, Sherrer ES, Dauphin DS, Shin S, Nelson AM, Ware CB, Zhan M, Song C-Z, Chen X, Brimble SN, Amanda M, Galeano MJ, Uhl EW, Damour KA, Chesnut J, Rao MS, Blau CA and Robins AJ. Self-renewal of human embryonic stem cells requires insulin-like growth factor-1 receptor and ERBB2 receptor signaling. Blood 110:4111-9, 2007.

Ware CB, Wang L, Mecham BH, Nelson AM, Dauphin DS, Buckingham B, Bar M, Lim R, Askari B, Gartler SM, Shen L, Issa J-P, Tewari M, Lamba DA, Pavlidis P, Duan Z, and Blau CA. Histone Deacetylase Inhibition Elicits an Evolutionarily Conserved Self-Renewal Program in Embryonic Stem Cells. Cell Stem Cell 4:359-369, 2009.

Erythropoietin and Cancer - Our Papers

Blau CA. Erythropoietin in Cancer: Presumption of Innocence? Stem Cells 2007; 25:2094-7.

Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, Barnato SE, Elverman KM, Courtney DM, McKoy JM, Edwards BJ, Tigue CC, Raisch DW, Yarnold PR, Dorr DA, Kunzel TM, Tallman MS, Trifilio SM, West DP, Lai SY, Henke M. Venous Thromboembolism and Mortality Associated with Recombinant Erythropoietin and Darbepoietin Administration for the Treatment of Cancer-Associated Anemia. JAMA 2008;299: 914-924.

Miller CP, Lowe KA, Valliant-Saunders K, Kaiser JF, Mattern D, Urban N, Henke M, Blau CA. Evaluating Erythropoietin-Associated Tumor Progression Using Archival Tissues from a Phase III Clinical Trial. Stem Cells 27:2353-61, 2009.

Miller CP, Valliant-Saunders K, Blau CA. Limitations of a murine transgenic breast cancer model for studies of erythropoietin-induced tumor progression. Translational Oncology 2010 Jun 1;3(3):176-80.

Miller CP, Urban N, Blau CA. Quantitative Comparison of Erythropoietin Receptor Levels in the Epithelial versus Endothelial Fractions of Primary Breast Tumors. Anticancer Res. 2011 Apr;31(4):1189-95.

Regulated Cell Therapy - Our Papers

Blau CA, Peterson KR, Drachman JG and Spencer DM. A proliferation switch for genetically modified cells. Proceedings of the National Academy of Sciences USA 94:3076-3081, 1997.

Jin L, Asano H and Blau CA. Stimulating cell proliferation through the pharmacologic activation of c-kit. Blood 91:890-897, 1998.

Jin L, Siritanaraktul N, Emery DW, Richard RE, Kaushansky K, Papayannopoulou Th and Blau CA. Targeted expansion of genetically modified bone marrow cells. Proceedings of the National Academy of Sciences USA 95:8093-8097, 1998.

Jin L, Neff T and Blau CA. Marrow sensitization to 5 fluorouracil using the ligands for flt-3 and c-kit. Experimental Hematology 27:520-525, 1999.

Richard RE, Wood B, Zeng H, Papayannopoulou Th and Blau CA. Expansion of genetically modified primary human hemopoietic cells using chemical inducers of dimerization. Blood 95:430-6, 2000.

Jin L, Zeng H, Otto KG, Richard RE, Emery DW and Blau CA. In vivo selection using a cell growth switch. Nature Genetics 26:64-66, 2000.

Otto KG, Jin L, Spencer DM and Blau CA. Cell Proliferation Induced by Forced Engagement of c-Kit and Flt-3. Blood 97:3662-3664, 2001.

Zeng H, Masuko M, Jin L, Neff T, Otto KG and Blau CA. Receptor specificity in the self-renewal and differentiation of primary multipotential hemopoietic cells. Blood 98:328-334, 2001.

Otto KG, Broudy VC, Lin N, Parganas E, Drachman JG, Luthi JN, Ihle JN and Blau CA. Membrane localization is not required for mpl function in normal hematopoietic cells. Blood 98:2077-2083, 2001.

Whitney ML, Otto K, Blau CA, Reinecke H and Murry CE. Control of myoblast proliferation with a synthetic ligand. Journal of Biological Chemistry 276:41191-41196, 2001.

Ieremia J and Blau CA. Limitations of a mouse model of sickle cell anemia. Blood Cells, Molecules & Diseases 28:146-151, 2002.

Li Z-Y, Otto KG, Richard RE, Ni S, Kirillova, I, Fausto, N, Blau CA and Lieber, A. Dimerizer-induced proliferation of genetically modified hepatocytes. Molecular Therapy 5:420-6, 2002.

Zhao S, Zoller K, Masuko M, Rojnuckarin P, Yang X, Parganas E, Kaushansky K, Ihle JN, Papayannopoulou Th, Willerford DM, Clackson T and Blau CA. JAK2, complemented by a second signal from c-kit or flt-3, triggers extensive self-renewal of primary multipotential hemopoietic cells. EMBO Journal 21:2159-2167, 2002.

Neff T, Horn PA, Valli VE, Gown AM, Wardwell S, Wood BL, von Kalle C, Schmidt M, Peterson LJ, Morris JC, Richard RE, Clackson T, Kiem HP, Blau CA. Pharmacologically regulated in vivo selection in a large animal. Blood 100: 2026-2031, 2002.

Richard RE and Blau CA. Selective expansion of genetically modified cord blood cells. Stem Cells 21: 71-78, 2003.

Berger C, Blau CA, Huang M-L, Iuliucci JD, Dalgarno DC, Gaschet J, Heimfeld S, Clackson T, Riddell SR. Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model. Blood 103:1261-9, 2004.

Richard RE, Weinreich M, Chang K-H, Ieremia J, Stevenson MM, Blau CA. Modulating erythrocyte mixed chimerism in a mouse model of pyruvate kinase deficiency. Blood 103:4432-4439, 2004.

Zhao S, Weinreich M, Blau CA. In vivo selection using a JAK2-based cell growth switch. Molecular Therapy 10:456-458, 2004.

Richard RE, DeClaro A, Yan J, Chien S, Kiem HP, Clackson T, Andrews R, and Blau CA. Heterogeneity among large animal models of in vivo selection. Molecular Therapy 10:730-740, 2004.

Emery DW, Tubb J, Nishino Y, Nishino T, Otto KG, Stamatoyannopoulos G, and Blau CA. Selection with a regulated cell growth switch increases the likelihood of expression for a linked γ-globin gene in vitro and in vivo. Blood Cells, Molecules & Diseases 34:235-47. 2005.

Gandi M, Ihara K, Cummings C, Pendergrass T, Blau CA and Drachman JD. Congenital Megakaryocytic Thrombocytopenia in Three Siblings: Molecular Analysis of Atypical Clinical Presentation. Experimental Hematology 33:1215-21, 2005.

Blau CA, Yan J, Neades R, Navas PA, Peterson KR. g-globin gene expression in CID-dependent multi-potential cells established from b-YAC transgenic mice. Journal of Biological Chemistry 280:36642-7, 2005.

Richard RE, Siritanaratkul N, Jonlin E, Skarpidi E, Heimfeld S, Blau CA. Collection of blood stem cells from patients with sickle cell anemia. Blood Cells Mol Dis 35:384-8, 2005.

Nagasawa Y, Wood B, Wang L, Lintmaer I, Guo W, Papayannopoulou Th, Harkey M, Nourigat C, Blau CA. Anatomical Compartments Modulate the Response of Human Hematopoietic Cells to a Mitogenic Signal In Vitro and In Vivo. Stem Cells 24:908-17, 2006.

Weinreich MA, Lintmaer I, Wang L, Liggitt D, Harkey M, Blau CA. Growth Factor Receptors as Regulators of Hematopoiesis. Blood 108:3713-21, 2006.

Miller CA, Blau CA. Using Gene Transfer to Circumvent Off-Target Effects. (2008) Gene Therapy 15:759-64.

Okazuka K, Beard BC, Emery DW, Schwarzwaelder K, Spector MR, Sale GE, von Kalle C, Kiem HP, Blau CA. Long-term Regulation of Genetically Modified Primary Hematopoietic Cells in Dogs. Mol Ther. 2011 Feb 15.

Genome Architecture Analysis - Our Paper

Duan Z, Andronescu M, Schutz K, McIlwain S, Kim YJ, Lee C, Shendure J, Fields S, Blau CA*, Noble WS*. A three dimensional model of the yeast genome. Nature 2010 May 20;465(7296):363-7. Epub 2010 May 2. (* denotes co-corresponding authors)